Chronic Reactivation of Persistent Human Herpesviruses EBV, HHV-6 and VZV and Heightened Anti-dUTPase IgG Antibodies Are a Recurrent Hallmark in Post-Infectious ME/CFS and is Associated With Fatigue
- PMID: 41451845
- DOI: 10.1002/jmv.70769
Chronic Reactivation of Persistent Human Herpesviruses EBV, HHV-6 and VZV and Heightened Anti-dUTPase IgG Antibodies Are a Recurrent Hallmark in Post-Infectious ME/CFS and is Associated With Fatigue
Abstract
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a debilitating disease with unknown etiology and heterogeneous symptomology for which there are no validated tests for definitive diagnosis. We examined 873 longitudinal serum samples from ME/CFS patients (n = 40) and 378 from healthy control individuals (n = 16) for differences in human herpesvirus and endogenous retrovirus-K (HERV-K) dUTPase IgG antibodies by ELISA. The results of this study demonstrate a significant increase in dUTPase IgG antibodies to the herpesviruses Epstein-Barr virus (EBV), human herpesvirus-6 (HHV-6) and varicella zoster virus (VZV) in ME/CFS compared to healthy-controls (p < 0.001). Notably, 72.5% (n = 29) of ME/CFS patients simultaneously co-expressed antibodies to multiple herpesvirus and HERV-K dUTPases compared to 31% (n = 5) of the healthy controls. Chi-square test analysis showed strong associations for EBV, HHV-6 and VZV dUTPase antibodies seropositivity (p < 0.001) and Spearman correlation analysis revealed significant positive associations of EBV and HHV-6 dUTPase IgG antibodies with fatigue. Further examination of the distribution of dUTPase antibodies across fatigue severity groups show that heightened dUTPase IgG levels cluster with ME/CFS patients exhibiting moderate and severe fatigue. These findings highlight the importance of examining herpesvirus dUTPase IgG across severity groups in aiding with current challenges for stratifying ME/CFS patients due to the heterogeneity in symptomology.
Keywords: Epstein‐Barr virus (EBV); Human endogenous retrovirus K (HERV‐K); Myalgic encephalomyelitis chronic fatigue syndrome (ME/CFS); antibodies; deoxyuridine triphosphate nucleotidohydrolase (dUTPase); fatigue; human herpesvirus 6 (HHV‐6); interferon gamma; varicella‐zoster virus (VZV).
© 2025 Wiley Periodicals LLC.
References
-
- Institute of Medicine of the National Academies., Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an illness Washington DC: The National Academies Press, 2015:pISBN 978‐0‐309‐31689‐7.
-
- K. Fukuda, S. E. Straus, I. Hickie, M. C. Sharpe, J. G. Dobbins, and A. Komaroff, “The Chronic Fatigue Syndrome: A Comprehensive Approach to Its Definition and Study,” Annals of Internal Medicine 121 (1994): 953–959.
-
- B. M. Carruthers, A. K. Jain, K. L. De Meirleir, et al., “Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Clinical Working Case Definition, Diagnostic and Treatment Protocols,” Journal of Chronic Fatigue Syndrome 11 (2003): 7–115.
-
- B. M. Carruthers, M. I. van de Sande, K. L. De Meirleir, et al., “Myalgic Encephalomyelitis: International Consensus Criteria,” Journal of Internal Medicine 270 (2011): 327–338.
-
- A. Vahratian, J. S. Lin, J. Bertolli, and E. R. Unger, “Myalgic Encephalomyelitis/Chronic Fatigue Syndrome in Adults: United States, 2021–2022,” NCHS Data Brief 488 (2023): 1–8.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
